Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular Testingmediviewcurative Gene Therapy Coverage & Prior Aut…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentmediviewcurativePolicy N/A

    FDA‑approved Gene Therapy Coverage Criteria (Section E)

    Customize your policy alerts

    Sign up for all mediviewcurative policy alerts

    Know when mediviewcurative releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines utilization management, coverage criteria, and site/specialist requirements for FDA-approved gene therapy products; affects providers requesting authorization for gene therapies under Curative Health Plan.

    Policy Summary
    Payermediviewcurative
    PolicyFDA‑approved Gene Therapy Coverage Criteria (Section E)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 4, 2026
    Last ReviewMar 4, 2026
    Next Review Date
    Key ActionObtain prior authorization and document CLIA‑certified genetic confirmation for the specific gene mutation before requesting therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11conditions/procedures in Section E
    ONEdose per lifetime per product (default limit)
    $2,125,000approximate one-time WAC cost for Zolgensma
    J3399HCPCS/J-code for onasemnogene abeparvovec
    1 dose/lifetimeHemgenix dosing policy
    ≥12 monthsminimum patient age for treatment

    Coverage Criteria and Product-specific Approval Rules

    Initial Therapy - Zolgensma

    Approval requires ALL of the following (A through G):

    A. Diagnosis: Patient has genetically confirmed spinal muscular atrophy (SMA) with bi-allelic SMN1 mutations documented by CLIA-certified laboratory testing (homozygous deletion of SMN1 exon 7 OR compound heterozygous mutation: deletion of exon 7 on one allele plus point mutation on the other); SMN2 copy number determined by quantitative assay (preferred 1–4 copies; ≥5 copies excluded by most payer policies)SMN2 copies 1-4

    CLIA-certified laboratory required

    B. Age: Patient is less than 2 years of age at time of infusion; premature neonate must reach full-term gestational age (≥39 weeks postmenstrual age) before infusion<2 years; PMA ≥39 weeks for premature neonate

    Per FDA label

    Policy Summary
    Payermediviewcurative
    PolicyFDA‑approved Gene Therapy Coverage Criteria (Section E)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 4, 2026
    Last ReviewMar 4, 2026
    Next Review Date
    Key ActionObtain prior authorization and document CLIA‑certified genetic confirmation for the specific gene mutation before requesting therapy.
    SourceLink
    On This Page
    Coverage Criteria and Product-specific Approval RulesBilling, Procedure, and Diagnosis CodesAuthorization, Documentation, and Operational RequirementsExclusions and Non-covered ScenariosPolicy Scope and BackgroundKey Definitions and Diagnostic ThresholdsEligibility Summary and Related NotesPolicy Revision History
    C. Weight: Patient weighs less than 13.5 kg at time of infusion (dosing is weight-based: 1.1 x 10^14 vg/kg)<13.5 kg

    Weight-based dosing

    D. Disease status: Patient does NOT have advanced SMA defined by complete paralysis of all limbs AND permanent ventilator dependence (tracheostomy with ≥16 hours/day invasive ventilation)

    Advanced disease exclusion

    E. Antibody testing: Anti-AAV9 antibody titer ≤1:50≤1:50
    F. Laboratory: Baseline laboratory evaluation obtained and acceptable: hepatic function (AST/ALT) within acceptable limits, platelet count within normal range, troponin‑I within normal range; baseline CBC, CMP, and coagulation studies obtained
    G. Treatment history & intensity: One dose per lifetime (no repeat administration); document prior SMA‑modifying therapy if present (nusinersen, risdiplam) and manage discontinuation per clinical judgment; infusion administered at a designated gene therapy center with pre‑treatment systemic corticosteroid and post‑infusion monitoring per protocol

    See intensity-of-service and monitoring schedules

    Not Medically Necessary - Deny Criteria for Zolgensma

    Does NOT meet criteria / Deny if ANY of the following:

    Denial triggers: Patient is ≥2 years at time of infusion; patient weighs ≥13.5 kg; advanced SMA (complete limb paralysis with permanent ventilator dependence); SMN1 mutation not confirmed by CLIA-certified genetic testing; SMN2 copy number ≥5; anti‑AAV9 antibody titer >1:50; active hepatic disease or ALT/AST >3x ULN; prior Zolgensma administration; active untreated infection at planned infusion; premature neonate not yet at full-term PMA (≥39 weeks); administration at a facility not designated/contracted for gene therapy; request to administer Zolgensma in combination with another SMA gene therapy

    Post-treatment Monitoring / Continued Stay

    Post-treatment monitoring and discharge criteria (medically necessary ongoing care):

    Monitoring schedule: Hepatic panel (AST/ALT): weekly x 4 weeks, biweekly x 4 weeks, then monthly x 12 months; platelet count: weekly x 4 weeks then per clinical judgment; troponin‑I at baseline and as clinically indicated; systemic corticosteroid taper (prednisolone ≥30 days) with taper adjustments based on LFTs; neuromuscular specialist assessments q3 months x 1 year then q6 months; motor milestone assessments as appropriate (CHOP‑INTEND, Bayley Scales, HFMSE)
    Inpatient admission justification: Inpatient admission justified only if: infusion reaction requiring >24‑hour monitoring; pre‑existing respiratory compromise needing post‑infusion monitoring; hepatotoxicity (ALT/AST >3x ULN) requiring IV steroids; thrombocytopenia developing post‑infusion; thrombotic microangiopathy (TMA)
    Discharge criteria: Post‑infusion observation ≥2 hours without adverse reaction; stable vital signs; prednisolone prescription with detailed taper schedule; lab monitoring schedule provided to family and PCP/neurologist; follow‑up with neuromuscular specialist within 1 week; family education on signs of hepatotoxicity and TMA

    Initial treatment criteria (Admission/Treatment)

    Approval requires ALL of the following (A through E):

    A. Diagnosis: Patient has confirmed biallelic RPE65 mutation‑associated retinal dystrophy documented by CLIA‑certified genetic testing; genetic confirmation options include a single pathogenic/likely pathogenic RPE65 variant in the homozygous state OR two pathogenic/likely pathogenic RPE65 variants in trans (segregation analysis when possible)
    B. Age: Patient is ≥12 months of age≥12 months
    C. Retinal viability (per eye to be treated): Sufficient viable retinal cells per eye determined by non‑invasive testing: posterior pole OCT thickness >100 µm OR ≥3 disc areas without complete atrophy on ophthalmoscopy>100 µm OR ≥3 disc areas
    D. Specialist and facility: Prescribed by a retinal surgeon experienced in subretinal injection at a Luxturna‑designated Center of Excellence
    E. Treatment parameters: One dose per eye per lifetime (bilateral treatment requires two separate procedures ≥6 days apart); patient has not previously received Luxturna or other gene therapy for retinal dystrophy1 dose per eye; bilateral separated ≥6 days
    Intensity of Service (must meet ≥1): Subretinal injection under general anesthesia or monitored sedation in OR; vitrectomy to access subretinal space; pre‑treatment systemic corticosteroid (prednisone 1 mg/kg/day x 7 days starting 3 days before each procedure with taper); post‑operative ophthalmic monitoring (IOP, retinal assessment)≥1 of listed

    Initial Therapy (SCD: Casgevy)

    Approval requires ALL of the following for Sickle Cell Disease indication (Casgevy):

    A. Diagnosis: Sickle cell disease confirmed by molecular/genetic testing with one of the following genotypes: HbSS, HbS/β0‑thalassemia, HbS/β+‑thalassemia, HbSC, or HbSD
    B. Age: Patient is ≥12 years of age>=12 years
    C. Disease severity: History of ≥2 severe vaso‑occlusive crises (VOCs) per year in each of the previous 2 years, including pain crises requiring ED visit or hospitalization, acute chest syndrome, priapism, or splenic sequestration>=2 VOCs/year x2 years
    D. Treatment history: At least one of: inadequate response to or intolerance of hydroxyurea; hydroxyurea contraindicated; or patient declined hydroxyurea after informed discussion
    E. Transplant eligibility: Eligible for HSCT but does NOT have an available 10/10 HLA‑matched related donor; has NOT received prior allogeneic HSCT; has NOT previously received Casgevy, Lyfgenia, or any other gene therapy
    F. Treatment delivery: One dose per lifetime administered at a qualified treatment center (QTC) with BMT capability; patient will undergo myeloablative conditioning with busulfan before Casgevy infusionone dose lifetime

    Initial Therapy (TDT: Casgevy)

    Approval requires ALL of the following for Beta‑thalassemia (TDT) indication:

    Diagnosis: Transfusion‑dependent beta‑thalassemia (TDT) confirmed by genetic testing
    Age: Patient is ≥12 years of age>=12 years
    Transfusion requirement: Requiring ≥8 RBC transfusions per year in each of the preceding 2 years>=8 transfusions/year x2 years
    Donor availability: No matched related donor available for allogeneic HSCT
    Dose and site: One dose per lifetime administered at a qualified treatment center (QTC) with BMT capability; myeloablative conditioning required prior to infusionone dose lifetime

    Not Medically Necessary / Exclusion Criteria

    Not medically necessary / Deny if ANY of the following are present:

    Denial conditions: Patient is <12 years of age; SCD genotype not confirmed by molecular/genetic testing; fewer than required VOCs/transfusions for the indication; available 10/10 HLA‑matched related donor (consider standard allo‑HSCT first); prior allogeneic HSCT; prior gene therapy (Casgevy, Lyfgenia, or other); active uncontrolled infection; myelodysplastic syndrome (MDS) or active malignancy; significant organ dysfunction precluding myeloablative conditioning (cardiopulmonary, hepatic, renal); administration at a facility not designated as a Casgevy qualified treatment center

    Intensity of Service

    Intensity of service required (must meet ALL):

    Intensity of Service: Stem‑cell mobilization (plerixafor + G‑CSF) and apheresis for CD34+ collection; myeloablative conditioning with busulfan prior to infusion; Casgevy infusion (autologous CRISPR‑edited CD34+ cells); inpatient BMT unit with protective isolation; daily labs, transfusion support, and neutropenic precautions during neutropenic period

    Lyfgenia - Initial Approval Criteria

    Lyfgenia approval requires ALL of the following (product-specific additions to Casgevy SCD criteria):

    Vector and indication: Lyfgenia uses a lentiviral vector (not CRISPR) delivering an HbA variant gene to patient HSCs and is indicated for SCD patients ≥12 years with recurrent VOCs; product shares core Casgevy eligibility elements
    Dosing: One dose per lifetime
    Conditioning: Myeloablative conditioning with busulfan required before infusion
    Treatment center: Must be administered at a bluebird bio Qualified Treatment Center (QTC)
    Additional monitoring: Enhanced malignancy surveillance per REMS: CBC at least every 3 months post‑infusion, assessment for clonal expansion at least twice in first year then annually, bone marrow evaluation as clinically indicated, and 15‑year long‑term follow‑up per FDA REMS

    Elevidys - Initial Approval Criteria

    Elevidys approval requires ALL of the following (A through F):

    A. Diagnosis: Confirmed mutation in the DMD gene by CLIA‑certified genetic testing and clinical diagnosis of Duchenne muscular dystrophy (Elevidys is NOT indicated for Becker muscular dystrophy)
    B. Age: Patient is ≥4 years of age (FDA approval for ambulatory ≥4 years; accelerated approval includes some non‑ambulatory patients ≥4 years)
    C. Antibody testing: Anti‑AAVrh74 total binding antibody titer <1:400 prior to infusion<1:400
    D. Medical status: No active infection at time of infusion; no significant liver dysfunction (ALT/AST <3x ULN, no acute hepatic disease); no clinically significant active cardiac disease or cardiomyopathy per treating physician
    E. Treatment specifics: One dose per lifetime (1.33 x 10^14 vg/kg IV infusion); patient has not previously received gene replacement therapy for DMD; administered at a Sarepta‑designated treatment center
    F. Corticosteroid protocol: Pre‑treatment with systemic corticosteroid per Elevidys prescribing protocol and post‑infusion corticosteroid tapering per protocol

    Level of Care - LOC Grid

    Level of care guidance (examples of indications for higher levels of care):

    ICU indications: Hypersensitivity reaction, hemodynamic instability, hepatotoxicity (e.g., significant transaminitis), severe thrombotic microangiopathy (TMA), respiratory failure
    Stepdown indications: Active infusion requiring q4h vitals, post‑conditioning engraftment monitoring, neurologic monitoring after intracerebral infusion (e.g., Kebilidi)

    Extended Stay Criteria

    Extended stay medical necessity criteria (continued inpatient stay requires documentation of ONE OR MORE):

    Extended stay triggers: Severe adverse event per FDA REMS (hepatotoxicity, TMA, hypersensitivity); failure to meet predefined discharge criteria from the FDA label monitoring; engraftment delay (autologous HSCT‑based therapies); infection or complication of conditioning regimen

    Document the specific trigger, supporting clinical evidence, and targeted intervention plan

    Elevidys (delandistrogene moxeparvovec-rokl) — Approval and intensity of service

    Covered when ALL of the following are met:

    Corticosteroid requirement: Pre‑treatment with systemic corticosteroid per Elevidys prescribing protocol and post‑infusion corticosteroid tapering per protocol
    Intensity‑of‑service elements: Single IV infusion (~1–2 hours) OR post‑infusion monitoring (minimum 3 hours observation) OR hepatic monitoring (LFTs weekly x4 wks, then biweekly x8 wks, then monthly x12 months) OR cardiac monitoring (troponin, BNP, echo baseline and post‑infusion)

    Elevidys — Not medically necessary / Deny conditions

    Do not approve if ANY of the following are present:

    Exclusion conditions: Becker muscular dystrophy (G71.02); anti‑AAVrh74 antibody titer ≥1:400; active infection at time of planned infusion; significant liver dysfunction or acute hepatic disease; prior gene replacement therapy for DMD; clinically significant active cardiac disease (e.g., cardiomyopathy with LVEF <40% or active myocarditis); administration at a non‑designated facility

    These are absolute exclusions

    Hemgenix — Approval criteria

    Approval requires ALL of the following:

    Diagnosis: Confirmed hemophilia B (factor IX deficiency) with FIX activity ≤2 IU/dL measured by one‑stage clotting assay or chromogenic assayFIX ≤2 IU/dL
    Clinical indication: Currently using FIX prophylaxis OR current/historical life‑threatening hemorrhage OR repeated serious spontaneous bleeding episodes
    Age/sex: Adult males (≥18 years of age)age ≥18
    Antibody and inhibitor testing: No pre‑existing anti‑AAV5 neutralizing antibodies that would prevent transduction (per Hemgenix prescribing information/clinical assessment) AND no history of FIX inhibitors (current or prior inhibitor titer ≥0.6 BU)inhibitor <0.6 BU
    Hepatic status: No active hepatitis B or C infection and no significant liver fibrosis or cirrhosis (FibroScan or equivalent assessment required)
    Site of care: Administered at a Hemophilia Treatment Center experienced in gene therapy; one dose per lifetime (2 x 10^13 gc/kg IV infusion)

    Single lifetime dose

    Hemgenix — Not medically necessary / Deny conditions

    Do not approve if ANY of the following are present:

    Exclusions: Hemophilia A (FVIII deficiency); female patients; patients <18 years; current or historical FIX inhibitor ≥0.6 BU; active hepatitis B or C; significant liver disease/cirrhosis; prior gene therapy for hemophilia B; FIX activity >2 IU/dL

    These are absolute exclusions

    Post-treatment monitoring and discharge

    Covered post-treatment monitoring and discharge requirements:

    Elevidys monitoring/discharge: Outpatient or 23‑hour observation typical; inpatient only for infusion reaction, hepatotoxicity, rhabdomyolysis, cardiac adverse event, or pre‑existing respiratory compromise. LFTs weekly x4 wks, biweekly x8 wks, monthly x12 months; troponin/BNP/echo per protocol; CK monitoring; motor function assessment (NSAA) q6 months. Discharge when observation completed without adverse reaction, stable vitals, corticosteroid taper schedule and lab monitoring schedule provided, neuromuscular follow‑up within 1–2 weeks, family education provided.
    Hemgenix monitoring/discharge: Outpatient infusion with ALT monitoring weekly x26 weeks; serial FIX activity monitoring to guide FIX prophylaxis discontinuation; discharge requires completed post‑infusion observation without adverse reaction, ALT monitoring schedule established with HTC, FIX prophylaxis plan documented, and hematology follow‑up within 1 week.ALT weekly x26 weeks

    Hemgenix Initial Therapy and Monitoring

    Hemgenix — Covered when ALL of the following are met

    Hemgenix coverage criteria: Outpatient infusion administration with post‑infusion ALT weekly x26 weeks and serial FIX activity monitoring to guide FIX prophylaxis management; discharge requires completed post‑infusion observation without adverse reaction, ALT monitoring schedule established with Hemophilia Treatment Center (HTC), FIX prophylaxis plan documented, and hematology follow‑up within 1 week.ALT weekly x26 weeks; FIX monitoring per HTC

    May discontinue prophylaxis if FIX levels sustained; goal LOS 1–2 days

    Skysona Initial Therapy Criteria

    Skysona — Approval requires ALL of the following

    Skysona approval criteria: Male aged 4–17 with early, active cerebral adrenoleukodystrophy (CALD); confirmed ABCD1 gene mutation by genetic testing; gadolinium enhancement on brain MRI indicating active demyelination; Loes score 0.5–9; Neurologic Function Score (NFS) ≤1; no available 10/10 HLA‑matched related donor for allogeneic HSCT; one dose per lifetime; myeloablative conditioning required before infusionLoes 0.5‑9; NFS ≤1; age 4‑17

    Intensity‑of‑service includes stem‑cell mobilization/apheresis/myeloablative conditioning and inpatient BMT‑unit stay

    Skysona Exclusions / NMN

    Skysona — Not medically necessary if ANY of the following are present

    Skysona exclusion criteria: Female patients; age <4 or >17 years; Loes score >9 (advanced disease); NFS >1; available 10/10 HLA‑matched related donor (allo‑HSCT preferred); prior gene therapy or HSCT

    Zynteglo Initial Therapy Criteria

    Zynteglo — Approval requires ALL of the following

    Zynteglo approval criteria: Confirmed transfusion‑dependent beta‑thalassemia requiring ≥8 RBC transfusions per year; no available HLA‑matched sibling donor; non‑β0/β0 genotype (Zynteglo is NOT indicated for β0/β0 genotype); one dose per lifetime; myeloablative conditioning required; age per FDA label (adults and pediatric patients)≥8 transfusions/year; non‑β0/β0 genotype

    Intensity‑of‑service same as autologous BMT (mobilization, apheresis, conditioning, infusion, engraftment)

    Zynteglo Exclusions / NMN

    Zynteglo — Not medically necessary if ANY of the following are present

    Zynteglo exclusion criteria: β0/β0 genotype; fewer than 8 RBC transfusions per year; available HLA‑matched sibling donor; prior gene therapy or HSCT

    Zynteglo (betibeglogene autotemcel) — Initial Approval

    Covered when ALL of the following are met

    Zynteglo initial therapy criteria: Confirmed beta‑thalassemia requiring ≥8 RBC transfusions per year AND no available HLA‑matched sibling donor AND non‑β0/β0 genotype AND one dose per lifetime AND myeloablative conditioning required AND age per FDA label (adults and pediatric patients)

    Intensity‑of‑service same as autologous BMT (mobilization, apheresis, conditioning, infusion, engraftment)

    Kebilidi — Initial Approval

    Covered when ALL of the following are met

    Kebilidi initial therapy criteria: Confirmed AADC deficiency by genetic testing showing biallelic DDC gene mutations AND biochemical confirmation (elevated 3‑O‑methyldopa and decreased HVA/VMA in CSF) AND patient is ≥18 months of age AND one dose per lifetime AND delivery by bilateral intraputaminal stereotactic neurosurgical injection under general anesthesia AND inpatient post‑operative monitoring (ICU then floor) AND brain MRI pre‑ and post‑procedure

    Expected inpatient LOS 5–7 days post‑neurosurgery

    Lenmeldy Initial Therapy

    Approval requires ALL:

    Lenmeldy (atidarsagene autotemcel) approval criteria: Confirmed metachromatic leukodystrophy (MLD) with biallelic ARSA gene mutations by genetic testing; late‑infantile form pre‑symptomatic or early symptomatic (before loss of walking) OR early juvenile form pre‑symptomatic; one dose per lifetime; myeloablative conditioning (busulfan) required; intensity‑of‑service per autologous BMT protocol

    Lenmeldy Not Medically Necessary

    Deny if ANY of the following:

    Lenmeldy exclusions: ARSA mutation not genetically confirmed; late‑onset (adult) form of MLD (not in FDA label); advanced late‑infantile form (non‑ambulatory, significant cognitive decline); advanced early juvenile form (symptomatic); prior gene therapy or HSCT

    Roctavian Initial Therapy

    Approval requires ALL:

    Roctavian (valoctocogene roxaparvovec) approval criteria: Confirmed severe hemophilia A (FVIII activity <1 IU/dL); adult males ≥18 years; currently using FVIII prophylaxis or history of life‑threatening hemorrhage; no current or prior FVIII inhibitors (≥0.6 BU); no anti‑AAV5 antibodies by screening assay; no active hepatitis B or C; no significant liver fibrosis or cirrhosis; one dose per lifetime; intensity‑of‑service: single IV infusion with post‑infusion hepatic monitoring (ALT weekly x 52 weeks)

    Roctavian Not Medically Necessary

    Deny if ANY of the following:

    Roctavian exclusions: Hemophilia B diagnosis; female patients; age <18 years; current/prior FVIII inhibitor; anti‑AAV5 antibodies detected; active hepatitis B or C; significant liver disease; prior gene therapy for hemophilia A

    Length of stay and extended stay criteria

    Goal LOS and extended stay documentation requirements

    Goal LOS: For uncomplicated Roctavian infusion, goal length of stay is 1–2 days for infusion observation per FDA label1-2 days
    Extended stay justification: If goal LOS is exceeded, continued inpatient stay requires documentation of ONE OR MORE specified medical‑necessity triggers and an intervention plan; triggers include severe adverse events per REMS (hepatotoxicity, TMA, hypersensitivity), failure to meet FDA label discharge criteria, engraftment delay, or infection/conditioning complication>=1 trigger

    This policy applies to FDA‑approved gene therapy products that involve direct genetic modification or gene replacement. Prior authorization is required for ALL gene therapy products and the default coverage limit is one lifetime dose per product unless the FDA label specifies otherwise. Coverage is limited to uses and patient populations consistent with FDA labeling; therapies for non‑FDA indications, use in patients who do not meet FDA age/weight criteria, repeat dosing when the label specifies single‑dose use, use in patients with label‑listed contraindications, or administration at non‑designated facilities are excluded. All gene therapy requests must document molecular/genetic confirmation of the target mutation from a CLIA‑certified laboratory and be prescribed by or in consultation with an appropriate specialist at a designated Curative Center of Excellence or contracted facility with gene therapy capability.

    Retinal dystrophies caused by pathogenic variants in genes other than RPE65 (for example, RPGR, CNGB3, CNGA3) are excluded from coverage for Luxturna. Coverage requires documentation of a confirmed biallelic RPE65 mutation by CLIA‑certified genetic testing; absence of that confirmation or identification of a non‑RPE65 genetic cause is a denial trigger.

    Luxturna and other product‑specific administrations must occur at designated centers. Administration of Luxturna at a facility that is not a Luxturna‑designated Center of Excellence (or otherwise lacks documented gene therapy administration capability) is excluded and will be denied.

    Casgevy must be delivered at a qualified treatment center with documented autologous HSC/gene therapy and BMT capability. Administration at a facility that is not designated as a Casgevy‑qualified treatment center is an exclusion and will result in non‑coverage.

    Lyfgenia is indicated only for the SCD population described in the product section and is NOT indicated for beta‑thalassemia. Patients with active myelodysplastic syndrome or other active hematologic malignancy are excluded. In addition, Lyfgenia recipients must comply with long‑term follow‑up requirements; patients who are unwilling to adhere to the specified 15‑year monitoring program meet exclusion criteria.

    Elevidys is approved for Duchenne muscular dystrophy (DMD) with CLIA‑confirmed DMD gene mutations. Use of Elevidys for Becker muscular dystrophy is explicitly not covered.

    Product‑specific exclusions include Elevidys exclusions (Becker muscular dystrophy, anti‑AAVrh74 titer ≥1:400, active infection, significant hepatic or cardiac disease, prior gene replacement therapy, administration outside designated centers) and Hemgenix exclusions (use for hemophilia A, female patients, patients <18 years, current or prior FIX inhibitor ≥0.6 BU, active hepatitis B/C or significant liver disease, prior gene therapy for hemophilia B, or FIX activity >2 IU/dL).

    Skysona and Zynteglo have distinct exclusion criteria summarized here. For Skysona, female patients, age <4 or >17 years, Loes score >9, NFS >1, available 10/10 HLA‑matched related donor, or prior HSCT/gene therapy are exclusions. For Zynteglo, a β0/β0 genotype, fewer than 8 RBC transfusions per year, an available HLA‑matched sibling donor, or prior gene therapy/HSCT are exclusionary.

    Zynteglo exclusions are explicit: patients with a β0/β0 genotype, those who have had fewer than 8 RBC transfusions per year, patients with an available HLA‑matched sibling donor, and those with prior gene therapy or HSCT do not meet coverage criteria for Zynteglo.

    Lenmeldy is indicated only when biallelic ARSA mutations are confirmed and for the specified disease stages (late‑infantile pre‑/early symptomatic or early juvenile pre‑symptomatic). Lenmeldy is excluded for patients without genetic confirmation, for late‑onset/adult MLD, for advanced symptomatic disease, or after prior gene therapy/HSCT.

    Roctavian is limited to the Roctavian eligibility described in the policy (adult males with confirmed severe hemophilia A meeting antibody/inhibitor and liver criteria). Roctavian is excluded for hemophilia B, female patients, patients <18 years, those with current or prior FVIII inhibitors, detectable anti‑AAV5 antibodies, active hepatitis B/C or significant liver disease, or prior hemophilia A gene therapy.

    Observation or 23‑hour observation may be appropriate for uncomplicated procedures or infusions per FDA labeling. Examples include uncomplicated Luxturna subretinal injection and uncomplicated Roctavian or Hemgenix infusions; however, higher levels of care (stepdown or ICU) are required when clinical events such as hypersensitivity, hemodynamic instability, hepatotoxicity, severe TMA, respiratory failure, or post‑conditioning engraftment concerns occur.

    Genetically confirmed spinal muscular atrophy with bi-allelic SMN1 mutations for Zolgensma

    Genetically confirmed SMA: Genetically confirmed spinal muscular atrophy with bi‑allelic SMN1 mutations; SMN2 copy number should be determined (1–4 copies preferred)

    Confirmed biallelic RPE65 mutation-associated retinal dystrophy

    Confirmed biallelic RPE65 mutation‑associated retinal dystrophy (either homozygous pathogenic/likely pathogenic variant OR two pathogenic/likely pathogenic variants in trans); diagnosis includes Leber congenital amaurosis (LCA), retinitis pigmentosa (RP), or other RPE65‑associated retinal dystrophy

    Confirmation of SCD genotype for Casgevy and TDT

    SCD and TDT genotype confirmation: Confirmation of sickle cell disease genotype for Casgevy eligibility (HbSS, HbS/β0, HbS/β+, HbSC, HbSD) and confirmation of transfusion‑dependent beta‑thalassemia for TDT indication; genetic testing required

    Sickle cell disease ≥12 years with recurrent VOCs (Lyfgenia indication)

    SCD indication (Lyfgenia): Sickle cell disease in patients ≥12 years with recurrent vaso‑occlusive crises (Lyfgenia indication); product‑specific REMS and monitoring apply

    Duchenne muscular dystrophy ≥4 years (Elevidys indication)

    DMD indication: Duchenne muscular dystrophy in patients ≥4 years with confirmed DMD gene mutation by CLIA‑certified testing (Elevidys indication); Becker muscular dystrophy is NOT covered

    Severe/moderately severe hemophilia B with FIX ≤2 IU/dL (Hemgenix indication)

    Hemophilia B indication: Severe or moderately severe hemophilia B with FIX activity ≤2 IU/dL to qualify for Hemgenix therapyFIX ≤2 IU/dL

    Early, active cerebral X-ALD in males 4-17 (Skysona)

    CALD indication (Skysona): Early, active cerebral X‑ALD in males 4–17 with confirmed ABCD1 mutation, gadolinium enhancement on MRI, Loes score 0.5–9, and NFS ≤1Loes 0.5-9; NFS ≤1

    Transfusion-dependent beta-thalassemia ≥8 RBC transfusions/year (Zynteglo)

    Zynteglo transfusion criterion: Transfusion‑dependent beta‑thalassemia requiring ≥8 RBC transfusions per year with non‑β0/β0 genotype and no available HLA‑matched sibling donor (Zynteglo indication)>=8 RBC transfusions/year

    AADC deficiency with genetic and biochemical confirmation

    AADC deficiency confirmation: Aromatic L‑amino acid decarboxylase (AADC) deficiency with genetic confirmation of biallelic DDC mutations plus biochemical CSF markers (elevated 3‑O‑methyldopa, decreased HVA/VMA)

    MLD with biallelic ARSA mutations (Lenmeldy)

    MLD indication (Lenmeldy): Metachromatic leukodystrophy (MLD) with biallelic ARSA mutations confirmed by genetic testing; approval requires disease‑stage criteria per label (late‑infantile pre‑/early symptomatic or early juvenile pre‑symptomatic)

    Billing, Procedure, and Diagnosis Codes

    HCPCS/J-CodesHCPCSCovered
    J3399injection, onasemnogene abeparvovec-xioi, per treatment
    ICD-10-PCS (inpatient)ICD-10
    XW033G4introduction of onasemnogene abeparvovec into peripheral vein, percutaneous approach (ICD-10-PCS if inpatient)
    Administration CPT CodesCPTCovered
    96413chemotherapy administration, IV infusion, first substance, first hour
    96415each additional hour
    ICD-10-CM for SMA indicationsICD-10
    G12.0infantile spinal muscular atrophy (Type I / Werdnig-Hoffmann)
    G12.1other inherited spinal muscular atrophy / SMA Type II-III
    G12.8other spinal muscular atrophies
    G12.9spinal muscular atrophy unspecified
    Z13.228encounter for screening for other metabolic disorders - newborn SMA screening
    Z14.8genetic carrier of other disease - SMN1 carrier
    Revenue CodesRevenue
    0250Pharmacy (Zolgensma product)
    0260IV Therapy (infusion services)
    0300Laboratory (LFTs, CBC, troponin, genetic testing)
    0636Drugs Requiring Detailed Coding (Zolgensma - WAC $2,125,000)
    0940Other Services (genetic counseling, neuromuscular assessment)
    Relevant ICD-10 and Procedure Codesmixed
    H35.50unspecified hereditary retinal dystrophy
    H35.51Stargardt disease - if RPE65-related
    H35.52pigmentary retinal dystrophy
    H35.53other dystrophies primarily involving the sensory retina
    H35.54dystrophies primarily involving the retinal pigment epithelium
    H31.20hereditary choroidal dystrophy unspecified
    H31.21choroideremia
    H31.29other hereditary choroidal dystrophy
    Z96.1presence of intraocular lens - post-vitrectomy if applicable
    J3398injection, voretigene neparvovec-rzyl, 1 billion vector genomes
    1–10 of 13
    1/2
    MS-DRG codes (inpatient)mixed
    DRG 116Intraocular Procedures w CC/MCC
    DRG 117Intraocular Procedures w/o CC/MCC
    Revenue codesmixed
    0360Operating Room revenue code
    0370Anesthesiology revenue code
    0250Pharmacy revenue code (Luxturna product)
    0636Drugs Requiring Detailed Coding (Luxturna)
    ICD-10-CM CodesICD-10
    D57.00Hb-SS disease with crisis unspecified
    D57.01Hb-SS with acute chest syndrome
    D57.02Hb-SS with splenic sequestration
    D57.03Hb-SS with cerebral vascular involvement
    D57.09Hb-SS with other specified complication
    D57.1Hb-SS disease without crisis
    D57.211Sickle-cell/Hb-C with acute chest syndrome
    D57.212Sickle-cell/Hb-C with splenic sequestration
    D57.219Sickle-cell/Hb-C with crisis unspecified
    D57.20Sickle-cell/Hb-C without crisis
    1–10 of 19
    1/2
    HCPCS/J-Codes, ICD-10-PCS, CPT Codesmixed
    J3392Injection, exagamglogene autotemcel, per treatment
    XW033L5Introduction of exagamglogene autotemcel into peripheral vein, percutaneous (ICD-10-PCS)
    38205Blood-derived HSC harvesting for transplantation, per collection
    38206Blood-derived HSC harvesting for transplantation, autologous
    MS-DRGmixed
    DRG 016Autologous Bone Marrow Transplant w/ CC/MCC
    DRG 017Autologous Bone Marrow Transplant w/o CC/MCC
    Sickle cell ICD-10 codesICD-10
    D57.00Hb-SS with crisis unspecified
    D57.01Hb-SS with acute chest syndrome
    D57.02Hb-SS with splenic sequestration
    D57.03Hb-SS with cerebral vascular involvement
    D57.09Hb-SS with other crisis
    D57.1Hb-SS without crisis
    D57.211sickle-cell/Hb-C with acute chest syndrome
    D57.219sickle-cell/Hb-C with crisis unspecified
    D57.20sickle-cell/Hb-C without crisis
    D57.411sickle-cell thalassemia with ACS
    1–10 of 15
    1/2
    DMD ICD-10 codesICD-10
    G71.01Duchenne muscular dystrophy
    G71.02Becker muscular dystrophy - NOT covered for Elevidys
    G71.0Muscular dystrophy unspecified - must be specified as Duchenne with genetic confirmation
    HCPCS/J-CodesHCPCSCovered
    J3394injection, lovotibeglogene autotemcel, per treatment
    MS-DRG crosswalkmixed
    DRG 016-017Autologous BMT
    Revenue codesRevenue
    0120, 0250, 0300, 0390, 0636Revenue codes (same as Casgevy)
    HCPCS/J-CodesHCPCSCovered
    J1413injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
    CPT CodesCPT
    96365IV infusion, initial \u22641 hour
    96366each additional hour
    ICD-10ICD-10
    D67hereditary factor IX deficiency - hemophilia B / Christmas disease
    MS-DRGmixed
    DRG 091-093Other Disorders of Nervous System (if inpatient)
    Revenue Codesmixed
    0250Pharmacy
    0260IV Therapy
    0300Lab
    0636Drugs - Elevidys
    Hemgenix HCPCS/CPT/DRG/Revenuemixed
    J1411injection, etranacogene dezaparvovec-drlb, per therapeutic dose
    96365-96366IV infusion
    DRG 813Coagulation Disorders
    0250Pharmacy (revenue code)
    0260IV Therapy (revenue code)
    0300Lab (revenue code)
    0636Drugs - Hemgenix WAC $3,500,000 (revenue code)
    Skysona HCPCS/DRG/Revenuemixed
    J3590unclassified biologic
    C9399unclassified drug/biological, new technology
    DRG 016-017Autologous BMT
    0120Revenue code
    0250Pharmacy (revenue code)
    0300Lab (revenue code)
    0390Revenue code
    0636Revenue code
    Zynteglo ICD-10-CM codesICD-10
    D56.1beta thalassemia - beta thalassemia major
    D56.5hemoglobin E-beta thalassemia
    D56.9thalassemia unspecified
    Skysona ICD-10-CM codesICD-10
    E71.520childhood cerebral X-linked adrenoleukodystrophy
    E71.521adolescent X-linked adrenoleukodystrophy
    E71.529X-linked adrenoleukodystrophy unspecified type
    E71.510X-linked adrenoleukodystrophy, non-cerebral forms
    E71.511adrenomyeloneuropathy
    HCPCS/J-CodesHCPCS
    J3590HCPCS/J-code: unclassified biologic
    C9399HCPCS/J-code: unclassified biologic
    MS-DRGmixed
    DRG 016-017Autologous BMT
    DRG 023-025Craniotomy/Intracranial Procedures
    CPT CodesCPT
    61720-61735CPT: stereotactic procedures
    Revenue CodesRevenue
    0120Revenue code
    0250Revenue code
    0300Revenue code
    0390Revenue code
    0636Revenue code
    0360OR revenue code
    0200ICU revenue code
    0610MRI revenue code
    ICD-10 Diagnosis CodesICD-10
    E70.81ICD-10-CM: aromatic L-amino acid decarboxylase deficiency
    E75.25ICD-10-CM: metachromatic leukodystrophy
    ICD-10 Diagnoses referencedICD-10
    E75.25metachromatic leukodystrophy
    D66hereditary factor VIII deficiency - hemophilia A
    HCPCS / J-codes (Lenmeldy)HCPCS
    J3590Unclassified biologics (listed in document for Lenmeldy)
    C9399Unclassified drugs or this-document listed for Lenmeldy
    HCPCS / J-code (Roctavian)HCPCS
    J1412injection, valoctocogene roxaparvovec-rvox, per therapeutic dose
    MS-DRG crosswalk (Lenmeldy)Revenue
    DRG 016-017Autologous BMT
    MS-DRG crosswalk (Roctavian)Revenue
    DRG 813Coagulation Disorders (if inpatient for Roctavian)
    Revenue codes (Lenmeldy)Revenue
    0120Revenue code listed
    0250Revenue code listed
    0300Revenue code listed
    0390Revenue code listed
    0636Revenue code listed
    Anti-AAV9 antibody titer — value
    Anti-AAV9 antibody titer≤1:50
    Weight threshold (<13.5 kg) — value
    Weight threshold<13.5 kg
    Age at infusion (<2 years) — value
    Age at infusion<2 years
    OCT retinal thickness (>100 µm) — value
    OCT retinal thickness>100 µm in posterior pole
    Ophthalmoscopy viable area (≥3 disc areas) — value
    Ophthalmoscopy viable area≥3 disc areas without complete atrophy
    VOCs per year (≥2) — value
    Vaso-occlusive crises (VOCs) per year≥2 VOCs per year in each of the previous 2 years
    RBC transfusions per year (≥8) — value
    RBC transfusions per year (TDT)≥8 RBC transfusions per year in each of the preceding 2 years
    Anti-AAVrh74 antibody titer (<1:400) — value
    Anti-AAVrh74 antibody titer<1:400
    Goal length of stay (Lyfgenia) — 30-45 days
    Goal length of stay (Lyfgenia)30-45 days
    FIX activity threshold for Hemgenix (≤2 IU/dL)
    FIX activity threshold (Hemgenix)≤2 IU/dL
    Anti-AAVrh74 titer exclusion for Elevidys (≥1:400)
    Anti-AAVrh74 titer exclusion (Elevidys)≥1:400 (exclusion)
    Transfusion frequency (≥8 RBC transfusions/year)
    Transfusion frequency (Zynteglo/TDT)≥8 RBC transfusions per year
    Loes score (0.5-9) for Skysona
    Loes score (Skysona)0.5-9
    Neurologic function score (NFS ≤1) for Skysona
    Neurologic function score (NFS)≤1
    Transfusion frequency (≥8 RBC transfusions/year) — Zynteglo
    Transfusion frequency (Zynteglo)>= 8 RBC transfusions/year
    Minimum age for Kebilidi (≥18 months)
    Minimum age for Kebilidi>= 18 months
    FVIII activity (<1 IU/dL) — Roctavian eligibility threshold
    FVIII activity (Roctavian eligibility)<1 IU/dL

    Authorization, Documentation, and Operational Requirements

    Prior Authorization

    Prior authorization required; one‑dose lifetime limit

    Prior authorization is required for all FDA‑approved gene therapy products; document and obtain prior authorization before administration. The policy imposes a lifetime limit of one dose per lifetime per product unless the FDA label specifies otherwise. Therapies must be administered at a Curative‑designated Center of Excellence or contracted facility with documented gene therapy capability and prescribed by or in consultation with an appropriate disease specialist.

    • Prior authorization required for ALL gene therapy products; no exceptions.
    • Default lifetime limit: ONE dose per lifetime per product unless FDA label states otherwise.
    • Site of care: Curative‑designated Center of Excellence or contracted facility with gene therapy capability.
    • Specialist requirement: prescribe by or consult relevant disease specialist (neurologist, hematologist, ophthalmologist, geneticist).
    Prior Authorization

    Prior authorization when Luxturna criteria A–E documented

    Prior authorization for Luxturna (voretigene neparvovec‑rzyl) requires documentation that all admission/treatment criteria A–E are met for each eye to be treated before authorization is granted.

    • Confirmed biallelic RPE65 mutation documented by CLIA‑certified genetic testing.
    • Patient is ≥12 months of age.
    • Per‑eye retinal viability: OCT posterior pole thickness >100 µm OR ≥3 disc areas without complete atrophy.
    • Prescription by an experienced retinal surgeon at a Luxturna‑designated Center of Excellence.
    • Treatment limits: one dose per eye per lifetime; bilateral procedures ≥6 days apart.
    Prior Authorization

    Prior authorization for Casgevy (J3392) — show eligibility and site

    Prior authorization for Casgevy (exagamglogene autotemcel, HCPCS J3392) must show the patient meets diagnosis/genotype, age, disease‑severity, transplant eligibility, and treatment delivery requirements before approval.

    • SCD confirmed by molecular/genetic testing with one of the listed genotypes (e.g., HbSS, HbS/β0, HbSC).
    • Patient is ≥12 years of age for SCD indications.
    • Documentation of disease severity (≥2 VOCs/year ×2 years) or transfusion dependence for TDT.
    • No available 10/10 HLA‑matched related donor and no prior allogeneic HSCT or prior gene therapy.
    • Treatment to occur at a qualified treatment center (QTC) with BMT capability; HCPCS J3392 and apheresis CPT codes (38205/38206) applicable.
    Prior Authorization

    Prior authorization — product‑specific documentation required

    Obtain prior authorization and submit product‑specific documentation demonstrating age, diagnosis/genotype, treatment center designation, and one‑time dosing limits for the requested therapy (e.g., Lyfgenia, Zynteglo).

    • Lyfgenia: J3394 — document SCD genotype, age ≥12, QTC site, one dose per lifetime, and REMS monitoring plan.
    • Zynteglo: bill under J3590/C9399 with evidence of ≥8 RBC transfusions/year and non‑β0/β0 genotype and absence of HLA‑matched sibling donor.
    • Ensure administration at product‑designated treatment center per product labeling.
    Prior Authorization

    Prior authorization required for Elevidys (J1413) and infusion codes

    Prior authorization is required for Elevidys (J‑code J1413) and associated infusion CPT codes; approval is contingent on meeting Elevidys‑specific clinical criteria and site requirements.

    • HCPCS J1413 must be authorized before administration.
    • Associated infusion CPT codes (96365/96366) and facility revenue coding should be included with the prior authorization request.
    • Approval requires meeting Elevidys clinical criteria (DMD genetic confirmation, age, antibody and medical status thresholds) and administration at a designated Sarepta treatment center.
    Prior Authorization

    Product‑specific prior authorization — confirm clinical eligibility

    Product‑specific prior authorization requires evidence that the patient meets the therapy’s clinical eligibility (e.g., confirmed mutation/genotype, age limits, transfusion history) and acknowledges the one‑dose lifetime limitation.

    • Skysona/Zynteglo: document genotype (ABCD1; non‑β0/β0 respectively), MRI/Loes/NFS or transfusion history as applicable.
    • Confirm one dose per lifetime and that no disqualifying prior HSCT or gene therapy exists.
    • Submit HCPCS/J‑code billing intent (J3590/C9399 or product J‑codes) with clinical documentation.
    Billing Rule

    Preauthorization — coding and billing instructions for gene therapies

    Preauthorization required for gene therapies should include billing plans: bill the drug under applicable HCPCS/J‑code (or J3590/C9399 for unclassified biologics) and include relevant procedure codes (e.g., 61720‑61735 for stereotactic neurosurgery) as part of the request.

    • Use J3590 or C9399 for unclassified biologics when a product‑specific HCPCS is not available.
    • Include procedure CPT codes for the delivery procedure (e.g., stereotactic neurosurgical CPTs 61720‑61735 for Kebilidi).
    • Attach anticipated MS‑DRG/revenue code crosswalk if inpatient admission is planned.
    Prior Authorization

    Prior authorization for Lenmeldy and Roctavian — confirm lab/genetic eligibility

    Prior authorization for Lenmeldy and Roctavian must confirm the therapy‑specific eligibility criteria (genetic confirmation for Lenmeldy; severe hemophilia A laboratory and antibody/inhibitor criteria for Roctavian) and note the single‑dose lifetime limitation.

    • Lenmeldy: document biallelic ARSA mutations and appropriate disease stage before authorization.
    • Roctavian: document FVIII activity <1 IU/dL, adult male status (≥18), absence of FVIII inhibitors and anti‑AAV5 antibodies, and negative hepatitis B/C and fibrosis assessment.
    • Record intention for one‑time dosing and planned post‑infusion hepatic monitoring.
    Prior Authorization

    Follow product REMS and payer prior authorization processes when not explicitly listed

    Where the document sections do not specify an explicit prior authorization process, follow the product‑specific REMS and Curative payer processes and obtain authorization per usual practice.

    • If product section lacks explicit prior authorization instructions, request prior authorization per payer workflow.
    • Ensure REMS enrollment and product‑specific monitoring plans are addressed in the authorization submission.
    Documentation Required

    Document prior SMA‑modifying therapy before Zolgensma

    If the patient has received prior SMA‑modifying therapy (nusinersen or risdiplam), document prior therapy in the authorization request and clinical record; manage discontinuation timing per clinical judgment around Zolgensma administration.

    • Document prior nusinersen (Spinraza) or risdiplam (Evrysdi) exposure.
    • Include plan for discontinuation or coordination of prior SMA‑modifying therapy in the treatment plan.
    Step Therapy

    Dose and sequencing requirement — Luxturna (one dose per eye; bilateral ≥6 days)

    For Luxturna, document dosing and sequencing: one dose per eye per lifetime and schedule bilateral procedures at least 6 days apart; include this dosing limitation in the prior authorization submission.

    • One dose per eye per lifetime.
    • If treating both eyes, schedule procedures ≥6 days apart and document in the plan.
    Documentation Required

    Hydroxyurea requirement — document prior response/intolerance or refusal

    For Casgevy and Lyfgenia SCD indications, prior authorization requires documentation of inadequate response/intolerance to hydroxyurea, hydroxyurea contraindication, or informed patient refusal when applicable.

    • Provide records of hydroxyurea trial and response or intolerance.
    • If hydroxyurea declined, include documented informed refusal discussion.
    Step Therapy

    Step therapy note — no step therapy for single‑dose gene therapies

    The policy states no step therapy is permitted for single‑dose gene‑replacement or gene‑modifying therapies; these are one‑time treatments administered at designated centers and should be authorized as such.

    • No prior step‑therapy sequence required for one‑time gene therapies.
    • Ensure authorization reflects one‑time dosing and designated treatment center delivery.
    Step Therapy

    Dose limitation — Hemgenix one dose per lifetime

    Hemgenix is limited to a single dose per lifetime; include this dose‑limitation in the authorization and billing documentation.

    • Hemgenix dosing: ONE dose per lifetime (2 × 10^13 gc/kg IV infusion).
    • No repeat dosing permitted.
    Prior Authorization

    Donor availability assessment before autologous HSCT‑based gene therapies

    Prior to approving some autologous‑HSCT–based gene therapies (e.g., Skysona, Zynteglo), assess and document availability of an HLA‑matched related donor and preference for standard allo‑HSCT where applicable.

    • Document evaluation for an available 10/10 HLA‑matched related donor.
    • If a matched donor exists, standard allogeneic HSCT should be considered first per guidelines; include rationale if proceeding with gene therapy.
    Step Therapy

    Step therapy — one‑time dose; no sequential step requirements

    Reiterate: no step therapy is specified; gene therapies are one‑time doses per lifetime and authorization must reflect single‑dose administration.

    • Authorization must indicate one dose per lifetime for the product requested.
    • Do not apply step‑therapy sequencing to these therapies.
    Documentation Required

    Required documentation — CLIA genetic confirmation and baseline labs

    Required documentation for any gene therapy authorization must include CLIA‑certified genetic confirmation of the specific causative mutation, relevant laboratory baselines, and disease‑specific data such as SMN2 copy number for SMA where applicable.

    • CLIA‑certified genetic test results verifying pathogenic variants for the relevant gene (e.g., SMN1, RPE65, ABCD1, ARSA, DMD, DDC).
    • SMN2 copy number for SMA (quantitative assay) when applicable.
    • Baseline labs: AST/ALT, platelet count, troponin‑I, CBC, CMP, coagulation studies as requested by product guidance.
    Documentation Required

    Genetic confirmation documentation — Luxturna (CLIA biallelic RPE65)

    For Luxturna, genetic confirmation must be documented with CLIA‑certified testing demonstrating biallelic RPE65 pathogenic or likely pathogenic variants (homozygous or two variants in trans).

    • Provide CLIA genetic report showing either homozygous RPE65 pathogenic variant or two pathogenic variants in trans (segregation analysis when available).
    • Attach clinical diagnosis (e.g., LCA, RP) that aligns with genetic findings.
    Documentation Required

    Ophthalmic and post‑op documentation required for Luxturna

    For Luxturna requests, include ophthalmic and postoperative documentation: per‑eye retinal viability (OCT >100 µm in posterior pole OR ≥3 disc areas without complete atrophy), pre/post‑op monitoring plans (IOP, retinal assessment), and scheduled follow‑up including second‑eye timing.

    • Per‑eye OCT showing posterior pole thickness >100 µm OR ophthalmoscopy showing ≥3 disc areas without complete atrophy.
    • Pre‑treatment corticosteroid plan and postoperative monitoring schedule (including IOP and retinal exams).
    • Follow‑up appointment with retinal surgeon within 1 week and plan for second eye ≥6 days after first if bilateral treatment planned.
    Documentation Required

    Prescriber and facility documentation — Luxturna designated surgeon/center

    The prescriber must be an experienced retinal surgeon at a Luxturna‑designated Center of Excellence; include facility designation and prescriber credentials in the authorization packet.

    • Include the prescribing retinal surgeon’s qualifications and confirmation that the center is a Luxturna‑designated Center of Excellence.
    • Document facility capabilities for subretinal injection and postoperative ophthalmic care.
    Documentation Required

    Required clinical documentation — Casgevy/Lyfgenia SCD/TDT requests

    For Casgevy and Lyfgenia authorizations, submit molecular/genetic confirmation of SCD/TDT genotype, age eligibility, prior treatment history (including hydroxyurea response/intolerance), transfusion history, absence of available matched donor, and planned BMT‑capable QTC site.

    • Molecular/genetic report confirming SCD genotype or TDT genotype.
    • For SCD: documentation of ≥2 VOCs per year ×2 years or hydroxyurea intolerance/decline; for TDT: documentation of ≥8 RBC transfusions/year ×2 years.
    • Proof of no available 10/10 HLA‑matched related donor and no prior allogeneic HSCT; identify the qualified treatment center (QTC) with BMT capability.
    Documentation Required

    Extended‑stay documentation requirement — justify when goal LOS exceeded

    When a planned inpatient stay exceeds the goal length of stay, document the specific medical‑necessity trigger, supporting clinical evidence, and a targeted intervention plan in the record and authorization.

    • Document which trigger justifies extended stay (e.g., hepatotoxicity, TMA, engraftment delay, infection).
    • Provide clinical data supporting the trigger and the planned interventions to address it.
    Documentation Required

    Diagnostic and antibody documentation — Elevidys (CLIA genetic confirmation and anti‑AAVrh74 titer)

    For Elevidys authorization, include CLIA‑certified genetic confirmation of DMD and anti‑AAVrh74 total binding antibody titer results (must be <1:400) as part of the prior authorization package.

    • CLIA genetic report confirming DMD gene mutation.
    • Anti‑AAVrh74 total binding antibody titer and laboratory method/result demonstrating <1:400.
    Documentation Required

    Required clinical documentation — Hemgenix (FIX activity, antibody/inhibitor, liver plan)

    Hemgenix authorizations must include confirmed diagnosis with FIX activity ≤2 IU/dL, antibody/inhibitor testing (no pre‑existing anti‑AAV5 neutralizing antibodies and no FIX inhibitor ≥0.6 BU), hepatitis B/C screening and liver fibrosis assessment, and an outpatient monitoring/discharge plan.

    • Laboratory confirmation of FIX activity ≤2 IU/dL by one‑stage or chromogenic assay.
    • Anti‑AAV5 neutralizing antibody assessment and documentation of no current/prior FIX inhibitor ≥0.6 BU.
    • HBV/HCV screening results and FibroScan or equivalent liver fibrosis assessment.
    • Post‑infusion plan: ALT monitoring schedule (weekly ×26 weeks), FIX monitoring, and Hematology follow‑up within 1 week.
    Documentation Required

    Hemgenix discharge documentation — ALT schedule, prophylaxis plan, follow‑up

    For Hemgenix discharge, document the ALT monitoring schedule with the Hemophilia Treatment Center, the FIX prophylaxis plan (continue until endogenous FIX production confirmed), and hematology follow‑up within one week.

    • ALT monitoring schedule (weekly ×26 weeks) documented and assigned to HTC.
    • Document plan for FIX prophylaxis continuation and criteria/monitoring for discontinuation.
    • Schedule hematology follow‑up within 1 week of discharge.
    Documentation Required

    Extended stay documentation — document trigger(s), evidence, and intervention plan

    When goal length of stay is exceeded for any gene therapy, explicitly document the trigger(s) and supporting clinical evidence; provide a targeted intervention plan to support continued inpatient coverage.

    • Identify the specific medical‑necessity trigger(s) causing extended stay.
    • Attach clinical data supporting the need for continued inpatient care and a plan for interventions and reassessment.
    Documentation Required

    Required documentation — Zynteglo genotype and transfusion history

    For Zynteglo requests, include genotype documentation demonstrating non‑β0/β0 status and transfusion history verifying ≥8 RBC transfusions per year as part of the prior authorization submission.

    • Genetic report documenting non‑β0/β0 beta‑globin genotype.
    • Transfusion records showing ≥8 RBC transfusions per year (as required).
    • Statement confirming no available HLA‑matched sibling donor.
    Documentation Required

    Lenmeldy genetic confirmation required (biallelic ARSA)

    Lenmeldy authorization must include CLIA‑confirmed genetic testing showing biallelic ARSA mutations; absence of confirmed biallelic ARSA is a denial trigger.

    • Submit genetic testing report confirming biallelic ARSA mutations.
    • Do not authorize if ARSA mutation is not genetically confirmed.
    Documentation Required

    Roctavian pre‑infusion documentation — FVIII, inhibitors, antibodies, viral/hepatic status

    Roctavian prior authorization must include pre‑infusion documentation: FVIII activity <1 IU/dL, adult male age ≥18, history of prophylactic FVIII use or life‑threatening hemorrhage, absence of FVIII inhibitors, negative anti‑AAV5 antibodies, and negative hepatitis B/C and liver fibrosis assessment.

    • FVIII activity result demonstrating <1 IU/dL.
    • FVIII inhibitor testing showing absence of current/prior inhibitors (≥0.6 BU).
    • Anti‑AAV5 antibody screening result (negative), HBV/HCV screening, and fibrosis assessment.
    • Document patient is adult male (≥18) and current prophylaxis or bleeding history.
    Denial Risk

    Denial risk — failure to obtain prior authorization or meet product criteria

    Prior authorization must be obtained before gene therapy; requests will be denied if prior authorization is not obtained or if the patient does not meet product‑specific FDA criteria (age, weight, genetic confirmation, facility designation).

    • Denials require licensed clinician review.
    • Do not proceed with administration without authorization; lack of authorization is grounds for denial.
    Denial Risk

    Denial triggers — Luxturna (missing genetic confirmation, age, retinal viability)

    Denials will be issued when product‑specific eligibility requirements are unmet—for Luxturna, examples include absence of CLIA‑confirmed biallelic RPE65 mutation, monoallelic mutation only, patient <12 months, or lack of viable retinal cells in the eye to be treated.

    • If RPE65 mutation is not confirmed by CLIA testing, request will be denied.
    • Monoallelic RPE65 mutation or patient age <12 months are denial triggers.
    • No viable retinal tissue in the target eye or administration at a non‑designated facility will result in denial.
    Denial Risk

    Triggers for denial — Casgevy (unmet genotype, age, VOC/transfusion, donor/HSCT history)

    Requests for Casgevy will be denied if required elements are missing or exclusion conditions are present, including patient age <12, unconfirmed SCD genotype, insufficient VOCs/transfusions, available 10/10 HLA‑matched related donor, prior allogeneic HSCT or prior gene therapy, active uncontrolled infection, MDS/active malignancy, significant organ dysfunction, or administration at a non‑qualified Casgevy treatment center.

    • Ensure SCD genotype is molecularly confirmed and disease severity (VOCs/transfusions) documented.
    • Confirm absence of a 10/10 HLA‑matched related donor and absence of prior HSCT or gene therapy.
    Denial Risk

    Exclusion triggers — Lyfgenia (active MDS/malignancy; refusal of long‑term follow‑up)

    Lyfgenia exclusions that will trigger denial/non‑coverage include active MDS or hematologic malignancy and patient unwillingness to comply with the 15‑year long‑term follow‑up requirement.

    • Active myelodysplastic syndrome or hematologic malignancy is an exclusion.
    • Documented unwillingness to participate in 15‑year REMS long‑term follow‑up is a denial trigger.
    Denial Risk

    Medical‑status denial triggers — Elevidys (active infection, liver or cardiac dysfunction)

    For Elevidys, medical‑status denial triggers include active infection, significant liver dysfunction (ALT/AST ≥3× ULN), or active cardiac disease at the time of infusion; these must be absent for authorization.

    • No active infection at infusion time.
    • No significant liver dysfunction (ALT/AST <3× ULN).
    • No clinically significant active cardiac disease per treating physician.
    Denial Risk

    Denial triggers — Elevidys (BMD, anti‑AAVrh74 ≥1:400, prior gene therapy, organ dysfunction)

    Elevidys will be denied if the diagnosis is Becker muscular dystrophy, anti‑AAVrh74 antibody titer is ≥1:400, active infection or significant hepatic/cardiac disease is present, prior gene replacement therapy for DMD occurred, or administration is at a non‑designated facility.

    • Becker muscular dystrophy diagnosis (G71.02) is excluded.
    • Anti‑AAVrh74 titer ≥1:400 is an exclusion/denial trigger.
    • Prior gene replacement therapy for DMD or significant organ dysfunction leads to denial.
    Denial Risk

    Lenmeldy denial triggers — missing ARSA confirmation or advanced/late disease

    Lenmeldy will be denied if ARSA mutations are not genetically confirmed, for late‑onset/adult MLD, advanced symptomatic disease stages, or if the patient has prior gene therapy or HSCT.

    • ARSA genetic confirmation required; absence leads to denial.
    • Late‑onset/adult MLD or advanced symptomatic disease are denial triggers.
    • Prior gene therapy or HSCT disqualifies the patient.
    Denial Risk

    Roctavian denial triggers — sex/age, inhibitors/antibodies, viral/hepatic exclusions

    Roctavian is denied when the patient has hemophilia B, is female, is <18 years old, has current/prior FVIII inhibitor, has anti‑AAV5 antibodies detected, active hepatitis B/C, significant liver disease, or prior gene therapy for hemophilia A.

    • Do not authorize Roctavian for females or patients <18 years.
    • Positive anti‑AAV5 antibodies or FVIII inhibitors (≥0.6 BU) are exclusionary.
    • Active hepatitis B/C or significant liver disease precludes authorization.
    Denial Risk

    Documentation‑trigger requirement — justify extended inpatient stay

    Failure to document one or more required medical‑necessity triggers when goal length of stay is exceeded may jeopardize continued inpatient coverage; include the trigger, evidence, and intervention plan in the medical record and authorization.

    • When LOS exceeds goal, document at least one medical‑necessity trigger (e.g., hepatotoxicity, TMA, engraftment delay).
    • Attach clinical evidence and a targeted intervention plan to support ongoing inpatient coverage.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Exclusions and Non-covered Scenarios

    Luxturna is not covered for patients who lack confirmation of a biallelic RPE65 mutation (e.g., monoallelic mutation only) or whose retinal dystrophy is due to non‑RPE65 genes. Requests for Luxturna in eyes without viable retinal cells, patients under 12 months of age, prior Luxturna in the requested eye, or administration at a non‑designated facility are also non‑covered.

    Casgevy is not covered when the required genotype is not molecularly confirmed, when the patient is younger than 12 years, or when an available 10/10 HLA‑matched related donor exists (allo‑HSCT should be considered first). Other exclusion scenarios include insufficient VOC/transfusion burden, prior allogeneic HSCT, prior Casgevy/Lyfgenia/other gene therapy, active uncontrolled infection, MDS/active malignancy, significant organ dysfunction precluding myeloablative conditioning, or administration at a non‑qualified center.

    Lyfgenia is explicitly not indicated for beta‑thalassemia. Elevidys is not indicated for Becker muscular dystrophy — Elevidys coverage is limited to genetically confirmed Duchenne muscular dystrophy; use in Becker muscular dystrophy is not covered.

    Product‑specific not‑covered scenarios include Elevidys use in Becker muscular dystrophy, Elevidys administration with anti‑AAVrh74 titer ≥1:400, active infection, significant liver or cardiac dysfunction, prior DMD gene replacement therapy, or non‑designated facility use. Hemgenix is not covered for hemophilia A, females, patients <18 years, patients with current or historical FIX inhibitors ≥0.6 BU, active hepatitis B/C or significant liver disease/cirrhosis, prior gene therapy for hemophilia B, or FIX activity >2 IU/dL.

    Skysona and Zynteglo have defined exclusion lists: Skysona excludes female patients, age outside 4–17 years, Loes score >9, NFS >1, available 10/10 HLA‑matched related donor, or prior gene therapy/HSCT. Zynteglo excludes β0/β0 genotype, fewer than 8 transfusions/year, available HLA‑matched sibling donor, or prior gene therapy/HSCT. Tests or requests lacking required genetic confirmation or transfusion/clinical thresholds should be denied.

    Requests that lack definitive genetic confirmation (for example, RPE65 biallelic confirmation for Luxturna, ABCD1 confirmation for Skysona, non‑β0/β0 genotype for Zynteglo, or DDC biallelic confirmation for Kebilidi) or that do not meet clinical thresholds (age, transfusion burden, Loes/NFS ranges, VOC/transfusion frequency) are not covered.

    Lenmeldy and Roctavian are covered only within the specific criteria in their sections. Use of Lenmeldy or Roctavian outside the listed genetic, age, disease‑stage, antibody/inhibitor, or prior‑therapy criteria (including prior HSCT or prior gene therapy) is not covered.

    Policy Scope and Background

    This policy governs FDA‑approved gene therapies involving direct genetic modification or gene replacement/addition. CAR‑T cell therapies are not included and are addressed under the separate oncology policy. Gene therapies generally require specialized administration at designated centers, REMS‑guided monitoring, and post‑infusion laboratory surveillance.

    Key Definitions and Diagnostic Thresholds

    Curative-designated Center of Excellence definition
    Curative-designated Center of ExcellenceCurative-designated Center of Excellence or contracted facility with documented gene therapy administration capability
    Biallelic RPE65 mutation definition
    Biallelic RPE65 mutationEither homozygous pathogenic/likely pathogenic RPE65 variant OR two pathogenic/likely pathogenic variants in trans (segregation analysis when possible)
    Retinal viability definition (OCT/ophthalmoscopy thresholds)
    Retinal viabilityPosterior pole OCT thickness >100 µm OR ≥3 disc areas of retina without complete atrophy on ophthalmoscopy in the eye to be treated
    Engraftment definition (ANC >500 for 3 consecutive days)
    EngraftmentAbsolute neutrophil count (ANC) >500 for three consecutive days indicating hematopoietic recovery after infusion
    Vaso-occlusive crisis definition
    Vaso-occlusive crisis (VOC)Severe SCD complication including pain crises requiring ED visit or hospitalization, acute chest syndrome, priapism, or splenic sequestration
    Myeloablative conditioning requirement (busulfan) definition
    Myeloablative conditioning requirementMyeloablative conditioning with busulfan required before infusion for autologous/allo-cell–based therapies (e.g., Casgevy, Lyfgenia, Skysona, Zynteglo, Lenmeldy)
    Anti-AAVrh74 antibody threshold for Elevidys (<1:400)
    Anti-AAVrh74 antibody threshold (Elevidys)Anti-AAVrh74 total binding antibody titer <1:400 required for eligibility; titer ≥1:400 is exclusion
    Post-infusion monitoring — serial labs and surveillance after AAV infusion
    Post-infusion monitoringSerial laboratory and clinical surveillance after AAV infusion including scheduled LFTs/ALT monitoring, cardiac biomarkers/imaging as indicated, CK and motor assessments for Elevidys, and FIX activity monitoring for Hemgenix
    Loes score definition and acceptance range for Skysona
    Loes scoreRadiographic scoring system to quantify extent of cerebral demyelination in CALD; policy acceptance range 0.5-9 for Skysona
    NFS definition and threshold for Skysona
    Neurologic function score (NFS)Neurologic function score; ≤1 required for Skysona approval (asymptomatic or mildly symptomatic)
    Transfusion-dependent beta-thalassemia definition (≥8 RBC transfusions/year)
    Transfusion-dependent beta-thalassemiaCondition defined by requirement for ≥8 RBC transfusions per year in each of the preceding years (eligibility for Zynteglo)
    AADC deficiency confirmation criteria (genetic + biochemical)
    AADC deficiency confirmationGenetic confirmation of biallelic DDC mutations plus biochemical CSF markers (elevated 3‑O‑methyldopa, decreased HVA/VMA)
    Confirmed MLD definition (biallelic ARSA mutations)
    Confirmed MLDDiagnosis requires biallelic ARSA gene mutations by genetic testing
    Severe hemophilia A definition (FVIII <1 IU/dL, adult males)
    Severe hemophilia AFVIII activity <1 IU/dL in adult males, with no FVIII inhibitors present
    Observation definition — outpatient or 23-hour observation sufficient
    ObservationOutpatient or 23-hour observation may be sufficient for uncomplicated infusion per FDA label
    Stepdown definition — care setting for active infusion/q4h vitals or engraftment monitoring
    Stepdown (Telemetry/PCU)Care setting for active infusion with q4h vitals or post-conditioning engraftment and neurologic monitoring

    Eligibility Summary and Related Notes

    Eligibility for gene therapies requires genetic confirmation of the specific disease‑defining mutation performed at a CLIA‑certified laboratory (for example, bi‑allelic SMN1 mutations for onasemnogene abeparvovec). The policy does not mandate a specific family history for eligibility; documentation should focus on molecular confirmation and required laboratory/clinical baseline testing.

    Product‑specific eligibility requirements are detailed in each product section. Examples include CLIA‑documented biallelic RPE65 testing for Luxturna; genotype confirmation and age/clinical thresholds for Casgevy/Lyfgenia; CLIA‑confirmed DMD mutation and anti‑AAVrh74 titer for Elevidys; FIX activity and antibody/inhibitor testing for Hemgenix; ABCD1 MRI/score/age criteria for Skysona; transfusion burden and genotype criteria for Zynteglo; biallelic DDC plus CSF biochemical confirmation for Kebilidi; biallelic ARSA confirmation for Lenmeldy; and FVIII activity and antibody/inhibitor screening for Roctavian. Refer to each product section for the full list of required elements.

    Prior testing requirements emphasize CLIA‑certified genetic testing for the relevant gene (for example, SMN1 for Zolgensma) and, where applicable, determination of key quantitative measures (e.g., SMN2 copy number). Antibody screening (anti‑AAV serotype) and baseline labs as specified per product are also required before authorization.

    For Zolgensma, documentation must include CLIA‑certified genetic confirmation of bi‑allelic SMN1 mutations and SMN2 copy number determination; age and weight thresholds and anti‑AAV9 antibody testing are part of eligibility and prior testing.

    RPE65‑related therapy (Luxturna) requires CLIA‑certified documentation of biallelic RPE65 pathogenic or likely pathogenic variants (either homozygous or two variants in trans). Ophthalmic assessments demonstrating retinal viability for each eye to be treated (posterior pole OCT thickness >100 µm OR ≥3 disc areas without complete atrophy on ophthalmoscopy) must be provided.

    Sickle cell disease and transfusion‑dependent beta‑thalassemia gene therapies (Casgevy, Zynteglo, Lyfgenia) require molecular/genetic confirmation of diagnosis, age eligibility, and documentation of disease severity (e.g., ≥2 VOCs/year for SCD or ≥8 RBC transfusions/year for TDT). Prior treatment history such as hydroxyurea response/intolerance and assessment for available HLA‑matched related donors must be documented.

    Elevidys eligibility requires CLIA‑confirmed DMD mutation and an anti‑AAVrh74 total binding antibody titer <1:400. Clinical status must exclude active infection, significant liver dysfunction, or clinically significant active cardiac disease at the time of infusion.

    Hemgenix eligibility requires laboratory confirmation of hemophilia B with FIX activity ≤2 IU/dL, assessment for anti‑AAV5 neutralizing antibodies and FIX inhibitors (no current or historical inhibitor ≥0.6 BU), and screening for hepatitis B/C and liver fibrosis. Hemgenix is restricted to adult males and administered at qualified Hemophilia Treatment Centers.

    Skysona eligibility requires a confirmed ABCD1 mutation, MRI evidence of active demyelination (gadolinium enhancement), Loes score between 0.5–9, and NFS ≤1 in males aged 4–17. An evaluation for available 10/10 HLA‑matched related donor is required and absence of prior HSCT/gene therapy must be documented.

    Kebilidi requires genetic confirmation of biallelic DDC mutations and biochemical CSF markers (elevated 3‑O‑methyldopa and decreased HVA/VMA). The minimum age is ≥18 months and stereotactic neurosurgical capacity and inpatient post‑op monitoring are required.

    Lenmeldy requires CLIA‑documented biallelic ARSA gene mutations and disease staging consistent with FDA labeling (late‑infantile pre/early symptomatic or early juvenile pre‑symptomatic). Genetic confirmation is mandatory and absence of prior gene therapy/HSCT is required for coverage.

    Policy Revision History

    2026-03-04policy_effectiveLatest

    Curative Health Plan master clinical decision criteria Section E — Gene Therapy became effective (Version 2.0).